Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 270,200 shares, an increase of 79.2% from the January 31st total of 150,800 shares. Currently, 10.2% of the shares of the company are sold short. Based on an average trading volume of 540,300 shares, the days-to-cover ratio is currently 0.5 days.

Traws Pharma Trading Down 1.5 %

TRAW traded down $0.05 on Friday, hitting $3.31. 72,130 shares of the company’s stock were exchanged, compared to its average volume of 96,156. The firm has a market capitalization of $12.08 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. Traws Pharma has a twelve month low of $3.06 and a twelve month high of $27.50. The company’s fifty day simple moving average is $7.26.

Institutional Investors Weigh In On Traws Pharma

Several institutional investors and hedge funds have recently bought and sold shares of TRAW. Geode Capital Management LLC bought a new position in Traws Pharma in the 4th quarter worth about $185,000. Renaissance Technologies LLC bought a new position in shares of Traws Pharma in the fourth quarter valued at approximately $89,000. Boothbay Fund Management LLC bought a new position in shares of Traws Pharma in the fourth quarter valued at approximately $252,000. Alyeska Investment Group L.P. bought a new position in shares of Traws Pharma in the fourth quarter valued at approximately $1,036,000. Finally, Millennium Management LLC bought a new position in shares of Traws Pharma in the fourth quarter valued at approximately $89,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.